(Q35809936)

English

Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly

scientific article published on 10 January 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly (English)

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

insulin glargine

1 reference

based on heuristic

inferred from title

Hannele Yki-Järvinen

6

object named as

H Yki-Järvinen

1 reference

Europe PubMed Central

10 August 2017

PMC publication ID

author name string

A J Varewijck

1

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

J A M J L Janssen

2

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

M Vähätalo

3

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

L J Hofland

4

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

S W J Lamberts

5

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

publication date

10 January 2012

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

55

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

4

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

1186-1194

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Insulin-like growth factor I: pros and cons of a bioassay.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3296010

11 July 2018

Insulin and its analogs: actions via insulin and IGF receptors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3296010

11 July 2018

Metformin: taking away the candy for cancer?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3296010

11 July 2018

Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3296010

11 July 2018

AMP-activated protein kinase inhibits IGF-I signaling and protein synthesis in vascular smooth muscle cells via stimulation of insulin receptor substrate 1 S794 and tuberous sclerosis 2 S1345 phosphorylation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3296010

11 July 2018

Treatment with insulin glargine (Lantus) increases the proliferative potency of the serum of patients with type-1 diabetes: a pilot study on MCF-7 breast cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3296010

11 July 2018

Igf-I bioactivity in an elderly population: relation to insulin sensitivity, insulin levels, and the metabolic syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3296010

11 July 2018

Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3296010

11 July 2018

Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3296010

11 July 2018

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3296010

11 July 2018

Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3296010

11 July 2018

Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3296010

11 July 2018

Insulin and insulin-like growth factor signalling in neoplasia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3296010

11 July 2018

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3296010

11 July 2018

Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3296010

11 July 2018

Metformin and reduced risk of cancer in diabetic patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3296010

11 July 2018

The LKB1 tumor suppressor negatively regulates mTOR signaling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3296010

11 July 2018

Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3296010

11 July 2018

Effects of stimulation of AMP-activated protein kinase on insulin-like growth factor 1- and epidermal growth factor-dependent extracellular signal-regulated kinase pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3296010

11 July 2018

Insulin inhibits growth hormone signaling via the growth hormone receptor/JAK2/STAT5B pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3296010

11 July 2018

Insulin-like growth factor-I and insulin-like growth factor binding protein-1 in a representative population of type 2 diabetic patients in Sweden.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3296010

11 July 2018

Insulin glargine is more potent in activating the human IGF-I receptor than human insulin and insulin detemir.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2435-7

21 January 2018

Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2435-7

21 January 2018

IGF-1 receptor signalling determines the mitogenic potency of insulin analogues in human smooth muscle cells and fibroblasts.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2435-7

21 January 2018

Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2435-7

21 January 2018

3.5 years of insulin therapy with insulin glargine improves in vivo endothelial function in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2435-7

21 January 2018

Glargine and regular human insulin similarly acutely enhance endothelium-dependent vasodilatation in normal subjects

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2435-7

21 January 2018

Biotransformation of insulin glargine after subcutaneous injection in healthy subjects

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2435-7

21 January 2018

The role of insulin-like growth factor (IGF) binding protein-2 in the insulin-mediated decrease in IGF-I bioactivity

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2435-7

21 January 2018

Insulin glargine and NPH insulin increase to a similar degree epithelial cell proliferation and aberrant crypt foci formation in colons of diabetic mice

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2435-7

21 January 2018

Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2435-7

21 January 2018

Does diabetes therapy influence the risk of cancer?

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2435-7

21 January 2018

Insulin-lowering effects of metformin in women with early breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2435-7

21 January 2018

Increased proteolysis of insulin-like growth factor-binding protein-3 (IGFBP-3) in noninsulin-dependent diabetes mellitus serum, with elevation of a 29-kilodalton (kDa) glycosylated IGFBP-3 fragment contained in the approximately 130- to 150-kDa ter

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3296010

25 September 2018

Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden

1 reference

https://pubmed.ncbi.nlm.nih.gov/22237688

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use

1 reference

https://pubmed.ncbi.nlm.nih.gov/22237688

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of total IGF-I assay methods using samples from Type I and Type II diabetic patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/22237688

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A highly sensitive and specific assay for determination of IGF-I bioactivity in human serum

1 reference

https://pubmed.ncbi.nlm.nih.gov/22237688

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Insulin-like growth factor binding protein-3 proteolysis in children with insulin-dependent diabetes mellitus: a possible role for insulin in the regulation of IGFBP-3 protease activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/22237688

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Normal values of circulating insulin-like growth factor-I bioactivity in the healthy population: comparison with five widely used IGF-I immunoassays

1 reference

https://pubmed.ncbi.nlm.nih.gov/22237688

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00125-011-2435-7

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35809936&oldid=2197776138"